Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Company Overview - Outlook Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of retinal diseases, including wet age-related macular degeneration (wet AMD) [5] - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive regulatory approval in the European Union and the United Kingdom for treating wet AMD, with a commercial launch expected in the first half of 2025 [5] Leadership Changes - Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately, succeeding Randy Thurman, who will continue as Lead Independent Director [1][2] - Sukhtian expressed gratitude for Thurman's leadership, highlighting his role in guiding the company from a preclinical stage to preparing for product launch [2] Strategic Focus - The company is preparing for the launch of LYTENAVA™ in the EU and UK while also focusing on completing a timely FDA resubmission in the United States [2] - The successful resubmission could lead to LYTENAVA™ being the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [5] Leadership Background - Faisal G. Sukhtian has been a member of the Board since 2017 and has extensive experience in operations, strategy development, and mergers and acquisitions in the biopharma sector [3] - Prior to GMS Holdings, Sukhtian worked in investment banking at J.P. Morgan, focusing on M&A, debt, and equity transactions [4]